Loraz and Copegus drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Loraz and Copegus. Common interactions include dizziness among females and haemorrhagic stroke among males.

The phase IV clinical study analyzes what interactions people who take Loraz and Copegus have. It is created by eHealthMe based on reports of 91 people who take Loraz and Copegus from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

91 people who take Loraz and Copegus together, and have interactions are studied.

What is Loraz?

Loraz has active ingredients of lorazepam. It is often used in stress and anxiety. eHealthMe is studying from 145,138 Loraz users for its effectiveness, alternative drugs and more.

What is Copegus?

Copegus has active ingredients of ribavirin. It is often used in hepatitis c. eHealthMe is studying from 15,106 Copegus users for its effectiveness, alternative drugs and more.

Number of Loraz and Copegus reports submitted per year:

Common Loraz and Copegus drug interactions by gender *:

female:

Dizziness
Rash
Diarrhoea
Arthralgia
Dyspnoea
Oropharyngeal pain
Pyrexia
Red blood cell count decreased
Amnesia
Blindness

male:

Haemorrhagic stroke
Agitation
Drug ineffective
Ear disorder
Joint swelling
Rash
Vertigo
Asthenia
Hypoaesthesia
Musculoskeletal pain

Common Loraz and Copegus drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Agranulocytosis
Pancreatitis
Suicide attempt

30-39:

Agitation
Anger
Cholecystitis
Congestive cardiomyopathy
General symptom
Irritability
Malaise
Multiple sclerosis relapse
Psoriasis
Pyrexia

40-49:

Suicidal ideation
Vomiting
Nausea
Anaemia
Dehydration
Rash
Muscular weakness
White blood cell count decreased
Fatigue
Irritability

50-59:

Staphylococcal infection
Vitreous floaters
Nausea
Haemorrhagic stroke
Vomiting
Aggression
Agitation
Fatigue
Decreased appetite
Weight decreased

60+:

Anaemia
Decreased appetite
Musculoskeletal pain
Platelet count decreased
Rash
Syncope
Pancytopenia
Septic shock
Diplopia
Dizziness

Common conditions people have *:

Depression: 17 people, 18.68%
Pain: 11 people, 12.09%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 10 people, 10.99%
Type 2 Diabetes: 7 people, 7.69%
High Blood Pressure: 7 people, 7.69%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 6 people, 6.59%
Bipolar Disorder (mood disorder): 6 people, 6.59%
Anaemia (lack of blood): 6 people, 6.59%
Gastric Ulcer (stomach ulcer): 5 people, 5.49%

* Approximation only. Some reports may have incomplete information.

Do you take Loraz and Copegus?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .